|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.5050 - 0.5500|
|52 Week Range||0.0400 - 6.0000|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.40|
LOS ANGELES, Jan. 24, 2019 -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of.
NEW YORK, NY / ACCESSWIRE / November 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Vitality Biopharma, Inc. (VBIO) with a Target Price of $3.50. Vitality Biopharma, Inc. (OTCQB: VBIO, ''Vitality'') is focused on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders, as well as pain and opioid addiction. Vitality's development pipeline is focused on a new class of cannabinoid prodrug pharmaceuticals called cannabosides.
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vitality Biopharma, Inc. (VBIO), a cure development company, dedicated to unlocking the power of cannabinoid "prodrugs" as a means to treat serious neurological and inflammatory disorders.
NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Vitality Biopharma, Inc. ( OTCQB: VBIO ) and Growlife, Inc. ( ...